DEERFIELD BEACH, Fla., April 24 /PRNewswire-FirstCall/ -- BioLok International Inc. , the manufacturer and worldwide distributor of leading-edge dental implant technology, today announced that Jerry P. Wildman, DDS has been selected to lead BoneGen-TR commercialization and development. BioLok intends to market BoneGen-TR, its new clinically safe, nano-composite, time release calcium sulfate product for bone augmentation, to dental industry professionals. Prior to joining BioLok, Dr. Wildman led a successful dental practice for 15 years before pursuing a career in management in 1997 with Ion Laser Technology.
The commercialization of BoneGen-TR is expected to commence in late July on a limited scale. The full market release is planned for September. Dr. Wildman will lead BioLok's product launch efforts and product development initiatives. Leveraging the technical support of BioLok's Orthogen research and development subsidiary, Dr. Wildman will be charged with guiding BoneGen-TR toward a prominent position in the $1 billion worldwide market for bone augmentation material.
Commenting on today's announcement, Bruce L. Hollander, BioLok's President & Chief Executive Officer, said: "BoneGen-TR is an important element to our growth strategy and we are excited to have appointed Jerry Wildman to lead our commercialization efforts for the product. Jerry brings a unique blend of management expertise and practical dental experience that should be instrumental in working with industry constituencies to stimulate demand and develop markets, outside of dentistry, for BoneGen-TR.
"This is an opportunistic time to introduce our unique and patented bone augmentation material. BoneGen-TR is a nano-composite material that fully resorbs into the body, leaving nothing but newly formed bone, which has significant advantages over many of the other products in the market. Existing natural products used in the bone augmentation and regeneration industry have for the past several months been negatively impacted by a myriad of health concerns. Among natural material sources, freeze dried bone has come under government investigation for unsafe procurement methods, while bovine-based products suggest exposure to the possibility of mad cow disease. Many ceramic substances do not fully resorb and are still questionable in their ability to grow new bone. With this backdrop, BoneGen-TR, a synthetic, should receive rapid adoption by dental professionals."
Based on medical grade calcium sulfate, a product proven safe for over 100 years, BioLok's BoneGen-TR has increased the time for resorbsion of calcium sulfate from 4 weeks to 18 weeks, allowing time for full and safe bone growth in large voids. BioLok will distribute the product directly in the United States dental market and internationally through distributors. The Company intends to identify strategic partners for distribution of the product in worldwide orthopedics and maxiofacial markets.
Dr. Wildman is a graduate of Northwestern University Dental School and practiced in Dunedin, Florida. He has a degree in biology and chemistry from the University of South Florida.
BioLok International Inc. is merging cell biology and technology to develop and market products for the dental implant and tissue regeneration markets. The Company is the worldwide manufacturer and distributor of the BioLok Precision Dental Implant System. BioLok offers a superior line of dental implants that incorporate many patented features and are synonymous with quality, fit of components, leading edge technology and design, and ease of use. Additional information is available on the Company's Web site at http://www.biolok.com.
With the exception of the historical information contained in the release, the matters described herein contain certain "forward-looking statements" that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. The statements contained in this release, which are not historical fact may be deemed to contain forward-looking statements, including, but not limited to, deployment of new services, growth of the customer base, and growth of the service area, among other items. Actual results may differ materially from those anticipated in any forward-looking statement with regard to magnitude, timing or other factors. Deviation may result from risk and uncertainties, including, without limitation, the Company's dependence on third parties, market conditions for the sale of services, technical factors affecting networks, availability of capital and other risks and uncertainties. More detailed information about these risk factors are set forth and may be updated from time to time in filings by BioLok International, Inc. with the Securities and Exchange Commission, including the Company's most recent quarterly report on Form 10-Q and other publicly available information regarding the Company. The Company disclaims any obligation to update information contained in any forward-looking statement.
BioLok International Contact: Investor Relations Contact: Bruce L. Hollander Jordan M. Darrow President/CEO Darrow Associates, Inc. 954-698-9998 631-367-1866 blh@biolok.comjdarrow@optonline.net
BioLok International Inc.CONTACT: Bruce L. Hollander President/CEO, BioLok International,+1-954-698-9998, blh@biolok.com; Investor Relations Contact, Jordan M.Darrow, Darrow Associates, Inc., +1-631-367-1866, jdarrow@optonline.net
Web site: http://www.biolok.com/
